Understanding Heart Disease

For decades, the medical community treated obesity and heart disease as related but separate problems. Cardiologists prescribed statins, blood pressure pills, and antiplatelet agents while weight management was left to primary care or dietitians. The SELECT trial changed this paradigm by proving that a weight management medication could directly reduce cardiovascular events in a high-risk population. the changing landscape of cardiovascular care

Atherosclerotic cardiovascular disease develops over decades as cholesterol, inflammatory cells, and fibrous tissue accumulate in artery walls. When plaques become unstable and rupture, the resulting blood clots cause heart attacks and strokes. While statins stabilize plaques by lowering LDL cholesterol, and antiplatelet agents reduce clot formation, a significant residual risk persists. In the FOURIER trial, patients who achieved an LDL below 30 mg/dL on evolocumab still experienced cardiovascular events at a rate of 9.8 percent over three years.

Obesity contributes to this residual risk through inflammation, insulin resistance, and hemodynamic stress, pathways that traditional cardiac medications do not fully address.

What the Research Shows

The SELECT Trial in Detail

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a randomized, double-blind, placebo-controlled trial conducted at 804 sites in 41 countries. It enrolled 17,604 adults aged 45 or older with a BMI of 27 or greater and established atherosclerotic cardiovascular disease but without diabetes.

Participants received either semaglutide 2.4 mg weekly or placebo in addition to standard cardiovascular care. The primary endpoint was the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, assessed over a mean follow-up of 39.8 months.

Results showed: 6.5 percent of semaglutide patients versus 8.0 percent of placebo patients experienced a primary endpoint event (HR 0.80, 95% CI 0.72-0.90). Nonfatal MI was reduced by 28 percent. Nonfatal stroke was reduced by 7 percent (not individually significant). Cardiovascular death was reduced by 15 percent. All-cause mortality trended lower (HR 0.81, 95% CI 0.71-1.01).

Subgroup Analyses

Pre-specified subgroup analyses from SELECT showed consistent benefit regardless of baseline BMI (above or below 35), age, sex, race, history of prior MI, prior stroke, peripheral artery disease, or baseline statin use. The benefit appeared slightly larger in patients with higher baseline CRP levels, suggesting that those with more inflammation derived greater protection.

FDA Approval and Label

In March 2024, the FDA approved a supplemental indication for Wegovy to "reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight." This made Wegovy the first weight management medication ever to receive a cardiovascular outcomes indication. Wegovy FDA approvals

Comparison to Other Cardiovascular Therapies

To put Wegovy's 20 percent MACE reduction in context: high-intensity statin therapy reduces MACE by approximately 25 to 30 percent, PCSK9 inhibitors by about 15 percent on top of statins, and the SGLT2 inhibitor empagliflozin by 14 percent in the EMPA-REG OUTCOME trial. Wegovy's effect size is competitive with these established therapies and addresses a different set of risk pathways.

How Wegovy May Help

Wegovy provides cardiovascular protection through a combination of metabolic, anti-inflammatory, and potentially direct vascular effects. how Wegovy protects the heart

Weight loss and hemodynamic relief: Participants in SELECT lost an average of 9.4 percent of body weight (less than the 15 percent seen in STEP 1, likely because SELECT enrolled an older, sicker population on more background medications). This weight loss reduced blood pressure by 3.4 mmHg, improved heart rate, and reduced the mechanical burden on the cardiovascular system.

Inflammation suppression: CRP decreased by approximately 38 percent in the semaglutide group. Since the CANTOS trial proved that reducing inflammation (via IL-1beta blockade) independently prevents cardiovascular events, Wegovy's anti-inflammatory effect is likely a significant contributor to its cardiovascular benefit.

Plaque biology: While direct human imaging data are limited, preclinical studies have shown that semaglutide reduces plaque area, decreases intraplaque hemorrhage, and increases markers of plaque stability in animal models of atherosclerosis.

Metabolic optimization: Improvements in insulin sensitivity, triglycerides, and lipid particle composition create a less atherogenic metabolic environment, slowing the formation of new plaques and reducing the vulnerability of existing ones.

Important Safety Information

Wegovy is an FDA-approved medication with a cardiovascular indication. Nonetheless, safety considerations apply:

GI side effects (nausea 44 percent, diarrhea 30 percent, vomiting 24 percent in STEP 1) can cause dehydration, which is especially risky in cardiac patients on diuretics, ACE inhibitors, or ARBs. Kidney function should be monitored during the titration phase.

Gallbladder events occur at elevated rates during rapid weight loss. In SELECT, cholelithiasis occurred in 1.6 percent of semaglutide patients versus 1.1 percent with placebo.

Wegovy carries a boxed warning regarding thyroid C-cell tumors in rodent studies. It is contraindicated in patients with medullary thyroid carcinoma or MEN2.

Patients should not discontinue existing cardiovascular medications (statins, antiplatelets, beta-blockers, ACE inhibitors/ARBs) when starting Wegovy. It is an addition to, not a replacement for, guideline-directed medical therapy. Wegovy alongside cardiac medications

Who Might Benefit

Wegovy's cardiovascular indication applies to a specific population, and the evidence is strongest for:

• Adults with established atherosclerotic cardiovascular disease (prior MI, prior stroke, symptomatic peripheral artery disease) and a BMI of 27 or greater, without diabetes
• Patients who are already on optimal statin and antihypertensive therapy but still carry residual cardiovascular risk related to obesity and metabolic dysfunction
• People with HFpEF and obesity, based on the STEP-HFpEF trial data
• Adults with cardiovascular disease and obesity-related comorbidities (obstructive sleep apnea, osteoarthritis) who would benefit from comprehensive weight-related risk reduction

For patients with type 2 diabetes and CVD, Ozempic or Victoza may be more appropriate depending on insurance coverage and clinical priorities.

How to Talk to Your Doctor

The cardiovascular indication fundamentally changes the conversation about Wegovy. It is no longer "a weight loss drug"; it is a cardiovascular risk-reduction therapy. Here is how to approach the discussion:

• Ask your cardiologist directly: "Based on the SELECT trial, am I a candidate for Wegovy for cardiovascular risk reduction?"
• Bring your cardiovascular history (prior events, stenting, bypass surgery) and current medication list
• Ask whether the cardiovascular indication improves your insurance coverage compared to a weight-management-only request
• Discuss monitoring: how often to check blood pressure, kidney function, and weight, and when to adjust other medications

The AHA and ACC have both incorporated GLP-1 RA therapy into their latest cardiovascular guidelines for patients with overweight/obesity and ASCVD, which provides additional support for the conversation. cardiovascular treatment guidelines and GLP-1

Frequently Asked Questions

Is Wegovy now considered a heart medication?

Wegovy has a dual identity. It is FDA-approved for both chronic weight management and cardiovascular risk reduction. Cardiologists may prescribe it specifically for its cardiovascular benefits in eligible patients, much like they prescribe SGLT2 inhibitors (originally diabetes drugs) for heart failure.

How long do I need to take Wegovy for heart benefits?

In the SELECT trial, cardiovascular benefit emerged within the first year and continued to accumulate over the full 39.8-month follow-up period. Current evidence suggests ongoing use is needed to maintain benefits, as weight regain after discontinuation may reverse both metabolic and cardiovascular improvements.

Does Wegovy work for heart disease even without major weight loss?

The mediation analysis of SELECT found that only about 40 percent of the cardiovascular benefit was explained by changes in weight, blood pressure, and lipids. This suggests Wegovy provides cardiovascular protection through mechanisms beyond weight loss alone, though greater weight loss is still associated with better outcomes.

Taking the Next Step

Wegovy's cardiovascular indication represents one of the most significant developments in heart disease treatment in recent years. For the first time, a weight management medication has demonstrated the ability to prevent heart attacks, strokes, and cardiovascular death.

At FormBlends, we help you understand these advances and take informed action. Explore our resources and bring what you have learned to your next appointment with your cardiologist or primary care provider. GLP-1 medications overview